The CDC has released updated clinical practice guidelines for opioid prescribing that include, for the first time, specific recommendations for emergency department acute pain management. The guidelines endorse multimodal analgesia as first-line therapy, establish new MME thresholds for ER prescriptions, and address the management of patients with opioid use disorder presenting to emergency settings.
The CDC's 2022 Clinical Practice Guideline for Prescribing Opioids was a significant improvement over the controversial 2016 version, which had been widely criticized for contributing to undertreatment of pain. The 2026 update goes further, adding emergency department-specific guidance that reflects the growing evidence base for multimodal analgesia and the evolving understanding of opioid use disorder as a medical condition requiring treatment rather than judgment.
Emergency departments occupy a unique position in the opioid prescribing landscape. They are responsible for managing acute pain across the full spectrum of severity — from minor injuries to post-surgical pain to cancer-related pain crises — often without the longitudinal patient relationship that allows primary care physicians and specialists to calibrate opioid therapy over time. ER physicians must make prescribing decisions rapidly, with limited information about a patient's opioid history, substance use disorder risk, and existing prescriptions.
At the same time, emergency departments have been identified as a significant source of opioid prescriptions that contribute to opioid use disorder. A 2024 study in JAMA Internal Medicine found that 6.1% of opioid-naive patients who received an opioid prescription in the emergency department went on to develop long-term opioid use within 12 months — a figure that underscores the importance of judicious ER opioid prescribing.
Previous CDC opioid prescribing guidelines had focused primarily on chronic pain management in primary care settings, with limited applicability to the acute pain scenarios that dominate emergency medicine practice. The 2026 update addresses this gap directly.
The guidelines recommend that emergency departments use multimodal analgesia — combining non-opioid analgesics (NSAIDs, acetaminophen, ketamine, regional nerve blocks) with opioids when opioids are indicated — as the standard approach to moderate-to-severe acute pain. The recommendation reflects evidence that multimodal approaches achieve equivalent or superior pain control with lower opioid doses and fewer opioid-related adverse effects. The guidelines specifically cite the Annals of Emergency Medicine ketamine vs. morphine trial as supporting evidence for ketamine as a first-line component of multimodal regimens.
For the first time, the CDC has established specific morphine milligram equivalent (MME) thresholds for opioid prescriptions issued at emergency department discharge. The guidelines recommend that ER discharge opioid prescriptions not exceed 50 MME per day and not exceed a 3-day supply for acute pain conditions without documented follow-up arrangements. For patients with documented severe acute pain conditions (fractures, post-procedural pain, cancer-related pain), a 7-day supply at up to 90 MME per day is considered appropriate with documented clinical justification.
The guidelines include a new section on the management of patients with opioid use disorder presenting to emergency departments, recommending that ERs implement universal OUD screening using validated tools (DAST-10 or AUDIT-C), offer buprenorphine initiation to patients with OUD who present to the ER for any reason (not only overdose), and establish warm handoff protocols to addiction medicine or primary care for patients who accept treatment. The recommendation to initiate buprenorphine in the ER is supported by multiple randomized trials demonstrating improved treatment engagement compared to referral alone.
The guidelines recommend that naloxone be co-prescribed with all opioid prescriptions issued from emergency departments, regardless of the patient's opioid history or the indication for the prescription. This recommendation extends the naloxone co-prescribing standard that several states have already adopted by regulation to a national clinical guideline level.
The 2026 guidelines are careful to address the risk of overcorrection — the undertreatment of legitimate acute pain that characterized the post-2016 period when the original CDC guidelines were widely misapplied as hard limits rather than clinical guidance. The guidelines explicitly state that "the goal of opioid prescribing guidance is to optimize pain management, not to minimize opioid prescribing for its own sake."
The guidelines note that undertreated acute pain has its own harms: it increases the risk of chronic pain development, impairs healing, causes unnecessary suffering, and can paradoxically increase long-term opioid use by allowing acute pain to become chronic. Emergency physicians are specifically instructed not to withhold opioids from patients with documented severe acute pain conditions based solely on concerns about opioid use disorder risk.
The American College of Emergency Physicians praised this aspect of the guidelines, noting that the 2016 CDC guidance had contributed to a culture of opioid reluctance in some emergency departments that resulted in inadequate pain management for patients with legitimate acute pain needs, including cancer patients, sickle cell disease patients, and patients with severe traumatic injuries.
The most clinically significant new recommendation for emergency medicine may be the guidance on buprenorphine initiation for OUD patients. Emergency departments have historically been reluctant to initiate buprenorphine, citing concerns about precipitated withdrawal, lack of follow-up infrastructure, and scope of practice questions. The 2026 guidelines address each of these concerns directly.
The guidelines note that low-dose buprenorphine initiation protocols — which use small initial doses to minimize precipitated withdrawal risk — have been validated in emergency department settings and are safe for use by emergency physicians without addiction medicine subspecialty training. They also note that the evidence for buprenorphine initiation in the ER is robust: a landmark 2015 NEJM trial found that ER-initiated buprenorphine was associated with a 78% higher rate of engagement in addiction treatment at 30 days compared to referral alone.
The Drug Enforcement Administration's 2023 elimination of the X-waiver requirement for buprenorphine prescribing removed the last regulatory barrier to ER buprenorphine initiation. The 2026 CDC guidelines now provide the clinical endorsement that many emergency physicians had been waiting for.
This article is eligible for 1.5 AMA PRA Category 1 Credits. See Clinical Insights for the assessment.